九周与一年曲妥珠单抗治疗早期人表皮生长因子受体2阳性乳腺癌:ShortHER III期随机试验10年更新
ShortHER III期随机非劣效试验比较9周与1年辅助曲妥珠单抗联合化疗治疗HER2阳性早期乳腺癌,中位随访9年,10年无病生存率长疗程组77%对短疗程组78%,总生存率89%对88%,非劣效性不能成立,1年曲妥珠单抗仍为标准治疗,N4+患者从1年治疗中明确获益。
要点
- 中位随访9年,10年无病生存率长疗程组77%对短疗程组78%,总生存率89%对88%。
- 非劣效性不能成立,1年曲妥珠单抗仍是HER2阳性早期乳腺癌的标准治疗。
- N0/N1-3患者长短疗程差异在数值上可忽略,N4+患者1年治疗明确获益。
核心结论
- ShortHER试验更新分析显示,1年曲妥珠单抗是HER2阳性早期乳腺癌的标准治疗,因为非劣效性不能成立。
- 数值上,低危或中危患者(N0/N1-3)长短疗程差异可忽略,而N4+患者从1年曲妥珠单抗中明确获益。
研究设计与样本
- III期随机非劣效试验ShortHER,比较9周与1年辅助曲妥珠单抗联合化疗治疗HER2阳性早期乳腺癌。
- 患者随机接受蒽环-紫杉类联合1年曲妥珠单抗(A组,长疗程)或9周曲妥珠单抗(B组,短疗程)。
- 本次报告第二个共同主要终点总生存(OS)、更新的无病生存(DFS)以及按激素受体状态、年龄和淋巴结状态的结果。
主要发现
- 中位随访9年,10年DFS长疗程组77%对短疗程组78%。
- 10年OS长疗程组89%对短疗程组88%。
- 按淋巴结状态,10年DFS长疗程组对短疗程组:N0 81%对85%;N1-3 77%对79%;N4+ 63%对53%。
- 按淋巴结状态,10年OS长疗程组对短疗程组:N0 89%对95%;N1-3 92%对89%;N4+ 84%对64%。
临床怎么用
- 原文结论认为1年曲妥珠单抗是HER2阳性早期乳腺癌的标准治疗,因为非劣效性不能成立。
- 原文指出数值上N0/N1-3患者长短疗程差异可忽略,而N4+患者从1年曲妥珠单抗中明确获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We present the final analysis of the phase III noninferiority, randomized ShortHER trial comparing 9 weeks versus 1 year of adjuvant trastuzumab with chemotherapy in patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (BC). Women with HER2+ BC were randomly assigned to anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or 9-week trastuzumab (arm B, short). Here, we report the second coprimary end point overall survival (OS), updated disease-free survival (DFS), and outcomes according to hormone receptor status, age, and nodal status. At a median follow-up of 9 years, 10-year DFS is 77% versus 78% in the long versus short arm, respectively. Ten-year OS is 89% versus 88% in the long versus short arm, respectively. 10-year DFS rates in the long versus short arm according to nodal status are N0 81% versus 85%; N1-3 77% versus 79%; and N4+ 63% versus 53%. Ten-year OS rates in long versus short arm according to nodal status are N0 89% versus 95%%; N1-3 92% versus 89%; and N4+ 84% versus 64%. The updated analysis of the ShortHER trial shows that 1-year trastuzumab is the standard treatment for patients with HER2+ early BC as noninferiority cannot be claimed. However, numerically, the differences for the patients at low or intermediate risk (N0/N1-3) is negligible, while patients with N4+ have a clear benefit with 1-year trastuzumab.
引用
- Conte P, Bisagni G, Piacentini F, et al. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial. J Clin Oncol. 2023. PMID: 37748109. doi:10.1200/JCO.23.00790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。